Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.
Fifty allogeneic stem cell transplant recipients were enrolled in a prospective cytomegalovirus pp65 antigenemia-guided preemptive therapy trial. Among these, 10 of 34 patients who received ganciclovir exhibited sustained and/or recurrent antigenemia despite treatment. Thirteen leukocyte preparations from these 10 subjects were screened for the presence of the most frequent cytomegalovirus UL97 mutations conferring ganciclovir resistance. None of these mutations were detected after mean and median ganciclovir exposures of 31.6 and 28.0 days, respectively.
Gilbert
C
C
Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec and Department of Medical Biology, University de Montréal, Québec, Canada.
Roy
J
J
Belanger
R
R
Delage
R
R
Beliveau
C
C
Demers
C
C
Boivin
G
G
D000956:Antigens, Viral / Q000032:analysis; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000187:drug effects* / Q000235:genetics*; D003586:Cytomegalovirus Infections / Q000517:prevention & control* / Q000821:virology*; D004352:Drug Resistance, Microbial; D015774:Ganciclovir / Q000494:pharmacology* / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007962:Leukocytes / Q000821:virology; D011446:Prospective Studies; D012008:Recurrence; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000956:Antigens, Viral; D000998:Antiviral Agents; D015774:Ganciclovir